Regulation of apoptosis.

Pleyer, L, Tinhofer, I, Greil, R, In: Hakan Mellstedt DSDBRG (Ed.) editors(s). ESMO Handbook of principles of translational Research.. p. 67-69.

Entwicklungen und Perspektiven in der Behandlung der Lymphatischen Neoplasien.

Pleyer, L, Desch, P, Greil, R, In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen.. p. 139-155.

A new sesquiterpene lactone sulfate from Reichardia gaditana (Asteraceae)

Zidorn, C, Ellmerer, EP, Heller, W, Johrer, K, Frommberger, M, Greil, R, Guggenberger, M, Ongania, KH, Stuppner, H Z NATURFORSCH B. 2007, 62(1): 132-134.

The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice

Namberger, K, Greil, R, Imaging decisions (Berlin, Germany). 2007, 10(4): 22-31.

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

Egle, A, Weiss, L, Gassner, F, Russ, G, Pleyer, L, Gunsilius, E, Tinhofer, I, Thaler, J, Petzer, AL, Greil, R BLOOD. 2008, 112(11): 1089-1089.

T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model

Egle, A, Pinon, JD, Heyder, C, Holler, C, Denk, U, Tinhofer, I, Greil, R BLOOD. 2008, 112(11): 1078-1078.

Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis.

Neureiter D, Kemmerling R, Ocker M, Seidlhofer C, Faber V, Stöcher M, Greil R, Dietze O. J Hematop. 2008 Jul,1(1):23-7. doi: 10.1007/s12308-008-0004-x. Epub 2008 Apr 19.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R Lancet Oncol. 2008 Sep,9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.

Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I. Blood. 2008 Sep 1,112(5):2168, author reply 2169. doi: 10.1182/blood-2008-05-158634.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG N Engl J Med. 2008 Aug 28,359(9):906-17. doi: 10.1056/NEJMoa0801479.